FUSION GENOMICS is a Vancouver-based company that is advancing molecular diagnostics by developing identification tests for pathogens using proprietary technologies in combination with Next Generation Sequencing. Its ONETest™ products, in combination with the FUSIONCloud™ data analysis platform, enable rapid identification of the genetic signatures of human pathogens and cancers accurately and economically. Furthermore, FUSION’s ONETest™ platform is currently being tested at various key opinion leaders in Canada and the European Union.
The company's mission is to provide global and local healthcare providers with the tools they need to perform both population surveillance and individual diagnosis of pathogens to prevent unnecessary deaths and halt the growing problem of disease drug resistance.
To do this, FUSION GENOMICS is developing highly sensitive and massively multiplex DNA/RNA sequencing-based diagnostics that combine its proprietary QUANTUMProbes™ technology with Next Generation Sequencing and its ever-expanding FUSIONCloud™ to bring results directly to the desktop or mobile devices. The use of FUSION GENOMICS’ reliably rapid, highly sensitive and cost-effective ONETest™ products will advance the field of molecular diagnostics beyond the limitations and shortcomings of molecular assays currently in use.
ONETest™ platform offers a complete 12 hours “Benchtop to Desktop” solution for next-generation sequencing based diagnostic testing of infectious diseases. It comprises the patent pending and proprietary UNIPrep™, QUANTUMProbes™ and the FUSIONCloud™ with 1000X the sensitivity over PCR and up to 9000X target enrichment over metagenome sequencing. The ONETest™ is able to identify any pathogen. Importantly, this platform has been validated with institutes and organizations around the world.
The AI eDNA ONETest proves the company's claims on high limit-of-detection, sensitivity and specificity by being the only test to date that can detect and genotype avian influenza from wetland sediments in wild bird habitats. Its upcoming Hepatitis C tests is similarly designed to give much improved clinically actionable data in a single test and FUSION GENOMICS has a pipeline of other tests such as HPV, MDR/XDR Tuberculosis (lat. Phthisis), blood screening multiplex, sepsis, etc.
In addition, the company's vision is of a world where humans are healthier because diseases are identified faster and treated/cured sooner through the use of assays that employ advanced sequencing technologies.